000			nab a22 7a 4500
999			_c16533 _d16533
003			PC16533
005			20210730134221.0
008			210708b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92349 _aPascual, Consuelo _eInstituto de Investigación i+12
100			_92134 _aAntequera, Desiree _eInstituto de Investigación i+12
100			_92135 _aBolos, Marta _eInstituto de Investigación i+12
100			_91777 _aCarro Díaz, Eva _eInstituto de Investigación i+12
245	0	0	_aPlasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model. _h[artículo]
260			_bNeurobiology of aging, _c2014
300			_a35(7):1582-95.
500			_aFormato Vancouver: Anitua E, Pascual C, Antequera D, Bolos M, Padilla S, Orive G et al. Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model. Neurobiol Aging. 2014 Jul;35(7):1582-95.
501			_aPMID: 24524966
504			_aContiene 72 referencias
520			_aImpaired growth factor function is thought to drive many of the alterations observed in Alzheimer's disease (AD) patients. Endogenous regenerative technology, PRGF (plasma rich in growth factor)-Endoret, is designed for the delivery of a complex pool of patient's own active morphogens that may stimulate tissue regeneration. We obtained and characterized PRGF-Endoret preparations from human blood. We used, as experimental approach in vivo, APP/PS1 mice, characterized by age-dependent brain amyloid-β (Aβ) accumulation. Intranasal administration of PRGF-Endoret to APP/PS1 mice resulted in an important decrease in brain Aβ deposition and tau phosphorylation. PRGF-Endoret-treated APP/PS1 mice also showed decreased astrocyte reactivity, and prevented protein synaptic loss. In vitro approaches demonstrated that PRGF-Endoret treatment modulated astrocyte activation, reducing inflammatory responses, and promoted Aβ degradation. Furthermore, PRGF-Endoret stimulated global improvements in anxiety, learning, and memory behaviors. Our findings show that PRGF-Endoret exerts multifunctional and complementary effects that result in the reversal of the broad range of cognitive deficits in AD, suggesting that PRGF-Endoret may hold promise as an innovative therapy in AD.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16533.pdf _ySolicitar documento
942			_2ddc _cART _n0